Studies showed that 83% of patients responded to treatment
The United States approved the first gene therapy in the nation on Wednesday — a treatment that uses a patient’s own immune cells to fight childhood leukaemia.
The treatment is made by Novartis and is called Kymriah (tisagenlecleucel).
This type of immunotherapy, known as a CAR-T cell therapy, was known by the term CTL019 until now.
It was approved by the U.S. Food and Drug Administration for children and young adult patients up to age 25 with a form of acute lymphoblastic leukaemia....................Read more
Source: The Hindu